Drug Type Small molecule drug |
Synonyms EGF-Au NP-Pc 4, PC-4 |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC39H35N9O2Si2 |
InChIKeyMXKIUUUHVLFVJF-UHFFFAOYSA-N |
CAS Registry135719-28-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Actinic Keratosis | Phase 1 | United States | 01 Sep 2004 | |
Bowen's Disease | Phase 1 | United States | 01 Sep 2004 | |
Breast Cancer | Phase 1 | United States | 01 Aug 2001 | |
Head and Neck Neoplasms | Phase 1 | United States | 01 Aug 2001 | |
Lymphoma | Phase 1 | United States | 01 Aug 2001 | |
Neoplasm Metastasis | Phase 1 | United States | 01 Aug 2001 | |
Sarcoma | Phase 1 | United States | 01 Aug 2001 | |
Skin Neoplasms | Phase 1 | United States | 01 Aug 2001 | |
Glioma | Preclinical | United States | 15 Apr 2011 |
Phase 1 | 11 | Photodynamic Therapy+silicon phthalocyanine 4 | fnpriedepp = cyvjjcfurq ehacrwjksp (zxevsguncl, oswtypsuiw - osgbpprsds) View more | - | 16 May 2019 |